CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. Prevention of skin cancer and reduction of keratotic skin lesions during ...

October 24, 2011 — In nonstraightforward bone marrow analysis, the presence of 30% or more CD34+ megakaryocytes is a strong indicator of megaloblastic anemia or a myeloid neoplasm, according to a ...

Immunofluorescence detection of the complement split product C4d along peritubular capillaries in renal allograft biopsies is the mainstay for the diagnosis of antibody-mediated rejection. The extent ...

Epoch-Making Breakthrough of the Stem-Cell Nutritional Supplementation CD34 Nu-Signals®, Currently Undergoing Rigorous Clinical Trials Conducted by Prestigious Medical Institutions to Validate Its ...

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group PURPOSE: To review recent advances in peripheral-blood ...

Expanding on the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutchinson Cancer Center’s expertise in providing Human CD34+ HSPCs, we have established a high-efficiency and ...

We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, ...

CAMBRIDGE, Mass. & HAIFA, Israel--(BUSINESS WIRE)--Minovia Therapeutics, a clinical-stage company focused on the development of cell-based Mitochondrial Augmentation Technology (MAT) to treat ...

Polycythemia vera is the ultimate phenotypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to which this mutation influences the behavior of the involved CD34+ ...

CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent ...